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Purpose: The clinical features of large cell carcinoma (LCC) of the lung have remained unclear due to the
low incidence of the disease. This study investigated the clinicopathological features and the surgical
outcome in patients with LCC.
Subjects: This study clinicopathologically evaluated 975 patients who had undergone a resection for non-
small cell carcinoma between 1994 and 2007. There were 57 (5.8%) patients with LCC among them.
Results: The LCC patients included 49 males and 8 females and included 9 patients with large cell
neuroendocrine carcinoma. All patients excluding 1 had a smoking habit. The mean smoking pack-year
index was 49.9 in the patients with LCC, 27.1 in 625 patients with adenocarcinoma, and 52.5 in 266
patients with squamous cell carcinoma, and this was signiﬁcantly higher in the patients with LCC than in
those with adenocarcinoma. The mean tumor diameter was 38 mm for LCC, 28 mm for adenocarcinoma,
and 39 mm for squamous cell carcinoma. The pathological stage was IA in 11 patients, IB in 11, II in 12,
IIIA in 16, IIIB in 5, and IV in 2. The post-operative 5-year survival rate was 60.5% for LCC, 64.3% for large
cell neuroendocrine carcinoma, 67.0% for adenocarcinoma, and 50.1% for squamous cell carcinoma.
Conclusion: The tumor diameter was signiﬁcantly larger for LCC than for adenocarcinoma at the time of
diagnosis. The proportion of smokers and the smoking pack-year index in patients with LCC were
signiﬁcantly higher than those of adenocarcinoma. The surgical results were similar between LCC and
other non-small cell lung carcinomas.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Lung cancer is among the most prevalent and lethal cancers
worldwide, thus presenting 28% cancer death.1,2 Despite years of
multidisciplinary management and research, the prognosis of
patients with lung cancer remains dismal, and the 5-year survival
rate in lung cancer is reported to be 10e15% throughout the world,
because the vast majority present with inoperable advanced
disease.3 Non-small cell lung cancer (NSCLC) accounts for 80% of all
lung malignant tumor, including adenocarcinoma, squamous cell
carcinoma, and large cell carcinoma. Large cell carcinoma (LCC) is
classiﬁed as an undifferentiated bronchogenic carcinoma with no
evidence of squamous or glandular maturation. In other words, it is
an exclusion diagnosis made after ruling out adenocarcinoma,
squamous cell carcinoma, and small cell carcinoma.4 The clinical
features of LCC of the lung have remained unclear because the
incidence is lower than 10%.
LCC is aggressive lung cancer, because of its rapid growth and
early tendency to metastasize.5 The treatment of LCC is based on: þ81 93 692 4004.
nagiri).
ciates Ltd. Published by Elsevier Ltthe strategy for NSCLC. Therefore, chemotherapy is planned using
the same regimen of NSCLC, except for large cell neuroendocrine
carcinoma. Platinum-based chemotherapy is currently the standard
treatment for LCC. However, LCC is frequently chemotherapy-
refractory cancer like other NSCLCs.6 Surgical resection is also
indicated for stage IeII disease as the ﬁrst line treatment. Previous
studies have suggested a dismal prognosis for large cell carcinoma,
even after a curative resection, however, the prognosis remains
poorly deﬁned.5,7,8 The present study retrospectively investigated
the clinicopathological features of LCC patients who underwent
surgery.
2. Patients and methods
The hospital records of 975 consecutive patients who under-
went a resection of non-small cell lung cancer between 1994 and
2007 were reviewed. The preoperative assessments included chest
roentgenography, computed tomography (CT) of the chest, upper
abdomen and brain. Clinical N2 status was deﬁned by the presence
of a lymph node more than 1 cm in a short axis diameter. Bone
scintigraphy was performed to detect any bone metastasis. MRI
(magnetic resonance imaging) of the brainwas routinely employedd. All rights reserved.
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cancer except for large
cell carcinoma
n ¼ 918
Average age 67.4 68.2
Male 49 (86.0%)* 613 (66.8%)
Female 8 (14.0%) 306 (33.3%)
Current and Ex Smoker 56 (98.2%)* 641 (69.8%)
Clinical stage
IA 13 (22.8%)** 408 (44.4%)
IB 12 (21.1%) 212 (23.1%)
II 11 (19.3%) 94 (10.3%)
IIIA 15 (26.3%) 122 (13.3%)
IIIB 6 (10.5%) 54 (5.9%)
IV 0 28 (3.1%)
Operative procedure
Pneumonectomy 2 (3.5%) 69 (7.5%)
Lobectomy bilobectomy 51 (89.5%) 729 (79.4%)
Segmentectomy 4 (7.0%) 56 (6.1%)
Partial resection 0 64 (7.0%)
Pathological stage
IA 11 (19.3%)* 374 (40.7%)
IB 11 (19.3%) 170 (18.5%)
II 12 (21.1%) 105 (11.4%)
IIIA 16 (28.1%) 143 (15.6%)
IIIB 5 (8.8%) 88 (9.6%)
IV 2 (3.5%) 38 (4.1%)
*p < 0.01, **p < 0.02.
Table 2










20 2 (3.5%) 313 (50.4%) 25 (10.0%)
20e40 19 (33.3%) 106 (17.1%) 61 (24.3%)
40e60 24 (42.1%) 137 (22.1%) 95 (37.8%)
60< 12 (21.1%) 65 (10.5%) 70 (27.9%)
Average of smoking index 49.9 27.1 52.5
*p < 0.01 (Large cell carcinoma vs Adenocarcinoma).
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a pathological diagnosis by a transbronchial lung biopsy, and to
evaluate endobronchial staging. The patients’ records, including the
clinical data, preoperative examination results, details of any
surgical operations, histopathological ﬁndings and the TNM stages
of all patients were also reviewed. The pulmonary function was
evaluated using spirometry and arterial blood gas analysis. A
ventilation-perfusion scan was routinely performed to predict
post-operative lung function. Predictive post-operative lung func-
tion was considered as operable if the forced vital capacity (FVC)
and forced expiratory volume in 1 s as percent of FVC (FEV1.0) was
greater than 900 ml/m2 and 600 ml/m2, respectively. All resected
specimens, including the primary tumor and resected hilar and
mediastinal lymph nodes, were examined to determine both the
tumor histology and the extent of lymph node metastases. The
histopathological ﬁndings were classiﬁed according to the World
Health Organization criteria, and the UICC TNM staging system (6th
edition) was employed.4,9 The deﬁnition of LCC is an undifferenti-
ated non-small cell carcinoma that lacks the cytologic and archi-
tectural features of small cell carcinoma and glandular or squamous
differentiation. The pathological diagnosis was performed by 2
pathologists in each case.
Follow-up information was obtained from all patients through
ofﬁce visits or telephone interviews either with the patient, with
a relative, or with their primary physicians. The patients were
evaluated every 3 months by chest roentgenography, and chest CT
scan and bone scintigraphy were obtained every 6 months for the
ﬁrst 2 years after surgery and annually thereafter. The mean
observation time was 3.5-years.
The survival curve was calculated by the KaplaneMeier method
and compared using the Log-rank test for the univariate analysis.
Categorical variables were compared by Fisher’s exact test. The
differences were considered to be signiﬁcant if the p value was less
than 0.05. The Statview V software program (Abacus Concept,
Berkeley, CA) was used for all statistical analyses.
3. Results
There were 975 patients who underwent a resection for non-
small cell lung cancer between 1994 and 2007, in the Second
Department of Surgery, University of Occupational and Environ-
mental Health. The current study evaluated 57 patients (5.8%) with
LCC who had undergone lung resection. The 57 patients included
49males and 8 females, indicating a signiﬁcantly greater number of
male patients (Table 1). The mean age of LCC patients was 67.4
years. All patients excluding 1 had a smoking habit. The average of
smoking pack-year index was 49.9 in the patients with LCC, 27.1 in
625 patients with adenocarcinoma, and 52.5 in 266 patients with
squamous cell carcinoma, and signiﬁcantly higher in the patients
with LCC than in those with adenocarcinoma (Table 2). The mean
tumor diameter was 3.8 cm for LCC, 2.8 cm for adenocarcinoma,
and 3.9 cm for squamous cell carcinoma, thus signiﬁcantly longer
for LCC than for adenocarcinoma (Table 3). Concerning the opera-
tive procedures, a pneumonectomy was performed in 2 patients,
a lobectomy and bilobectomy in 51, and a segmentectomy in 4.
Nine of the 57 LCC patients were diagnosed to have large cell
neuroendocrine carcinoma. The pathological stage of patients with
LCC, excluding large cell neuroendocrine carcinoma, was IA in 8
patients, IB in 9, IIA in 2, IIB in 8, IIIA in 14, IIIB in 5, and IV in 2. The
patients in stage IIIB included 3 patients with pulmonary metas-
tasis in the same lobe of the primary tumor, and 2 patients with
invasion of a great vessel (pulmonary artery or pulmonary vein) in
the mediastinum. One of the patients at stage IV had pulmonary
metastasis in the ipsilateral different lobe of the primary tumor,
and the other patient had metastasis in the chest wall, which wasresected with the primary tumor. The pathological stage of patients
with large cell neuroendocrine carcinoma was and IA in 3 patients,
IB in 2, II in 2, and IIIA2 in 2. The post-operative 5-year survival rate
was 61.5% for LCC, 67.0% for adenocarcinoma, and 50.1% for squa-
mous cell carcinoma. Adenocarcinoma showed a signiﬁcant better
survival than squamous cell carcinoma (p < 0.05), however, there
was no signiﬁcant difference in the post-operative prognosis either
between LCC and adenocarcinoma, or LCC and squamous cell
carcinoma (Fig. 1). The 5-year survival rate of LCC except for large
cell neuroendocrine carcinoma was 60.5%, and that of large cell
neuroendocrine carcinoma was 64.3% (Fig. 2)
4. Discussion
NSCLC are classiﬁed into three major subgroups; adenocarci-
noma, squamous cell carcinoma, LCC, and into several minor
subgroups. The incidence of LCC is lower than 10%.4 The diagnosis
of LCC is made by exclusion of other cell types of NSCLC and small
cell carcinoma, and it is so-called the “wastebasket category”.4
Therefore, preoperative diagnosis is sometimes difﬁcult, because
of the small amount of sample obtained in transbronchial lung
biopsies. Larger surgical specimens often yield more information,
and the diagnosis often changes to adenocarcinoma or squamous
Table 3









Maximum tumor size (cm)
1 1 (1.8%) 58 (9.3%) 9 (3.5%)
1e2 14 (24.6%) 206 (33.1%) 35 (13.5%)
2e3 13 (22.8%) 155 (24.9%) 58 (22.4%)
3e4 9 (15.8%) 109 (17.5%) 52 (20.1%)
4e5 6 (10.5%) 39 (6.3%) 38 (14.7%)
5< 14 (24.5%)* 55 (8.8%) 67 (25.9%)
Average of tumor size (cm) 3.8* 2.8 3.9














Fig. 2. Comparison of the overall survival curves between large cell carcinoma and
large cell neuroendocrine carcinoma. The post-operative 5-year survival rates of large
cell carcinoma, and large cell neuroendocrine carcinoma were 60.5% and 64.3%,
respectively.
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squamous cell carcinoma or adenocarcinoma preoperatively
because of the indeﬁnite diagnosis criteria.10
Large-scale surveys regarding the surgical results of the patients
with lung cancer were conducted by the Japan Joint Committee of
Lung Cancer Registry.11,12 These national surveillance data
summarized 6644 and 13,010 patients that had undergone surgery
in 1994 and 1999, respectively. They showed that the incidence of
LCC was 3.6% in each investigation, suggesting LCC is a relatively
rare subtype in Japan. According to these studies, the 5-year
survival rate of LCC is 46.7% and 45.5%, respectively, and the
prognosis of LCC is signiﬁcantly poorer than that of adenocarci-
noma. In the present study, the incidence of LCC was 5.8%, and the
5-year survival rate of LCC was 61.5%. The prognosis was unfavor-
able in comparison to adenocarcinoma, but not signiﬁcantly.
Therefore, the surgical treatment is performed with same indica-
tion according to other NSCLC, which is complete resection is the
ﬁrst line of treatment. Chemotherapy for LCC is administered
according to the strategy of NSCLC. Cisplatin/pemetrexed signiﬁ-
cantly improved overall survival more than cisplatin/gemcitabine
in patients with LCC (10.4 vs. 6.7 months, respectively; p < 0.03),
suggesting that LCC should be considered together with adeno-
carcinoma (the non-squamous subgroup).6,13
Smoking is known tohave a strongassociationwith the incidence
of squamous cell carcinoma and small cell carcinoma in comparison
to adenocarcinoma.14,15However, LCCoccurspredominantly inmale
and smokers.10 All patients excluding 1 were smokers, and the
smoking pack-year index in patients with LCC were signiﬁcantly
higher than those of adenocarcinoma, in this study. Another clinical














Fig. 1. Comparison of the overall survival curves according to the histology. The overall
survival in each period was analyzed by the KaplaneMeier method. The post-operative
5-year survival rates of adenocarcinoma, large cell carcinoma, and squamous cell
carcinoma were 67.0%, 61.5, and 50.1%, respectively. The survival rate of adenocarci-
noma was signiﬁcantly better than that of squamous cell carcinoma (p < 0.01).peripheral lung. LCC is reported to often form a large tumor mass at
the time of diagnosis.5,10 The tumor is often accompanied by central
necrosis.10 The tumor diameterwas signiﬁcantly longer for LCC than
for adenocarcinoma, although tumor doubling time in these
histology could not be evaluated in the present study.
LCC with neuroendocrine features was separated as a large cell
neuroendocrine carcinoma the World Health Organization (WHO)
in 1999.4 The histological features such as organoid nesting,
trabecular, rosette-like and palisading patterns are conﬁrmed by
immunohistochemistry and electron microscopy. Although large
cell neuroendocrine carcinoma is categorized as a variant of LCC,
the biological behavior of large cell neuroendocrine carcinoma is
similar to small cell carcinoma, indicating more aggressive clinical
characteristics with an unfavorable prognosis.16,17 However, no
difference was observed between LCC with or without neuroen-
docrine features in the present study. This may be an effect of the
small series and low incidence of this subgroup (9 cases). Surgical
treatment alone is not sufﬁcient for large cell neuroendocrine
carcinoma. Adjuvant chemotherapy with cisplatin/VP-16 as
chemotherapeutic regimen similar to those for small cell lung
cancer is effective for large cell neuroendocrine carcinoma.18,19
However, there have so far been only a few trials using chemo-
therapy or radiotherapy for LCC, because of its low incidence.
The post-operative prognosis of LCC was similar to that of other
non-small cell lung carcinomas. A surgical resection is also rec-
ommended as the ﬁrst line treatment for LCC with lung cancer. The
present study suggests that LCC presents with a large mass at the







Reports describing data obtained from research conducted in
human subjects must contain a statement in the Methods section
indicating approval by the institutional review board and afﬁrma-
tion that informed consent was obtained from each patient.
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